Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Parlavecchio Caryn | CHRO | Aug 16 '24 | Sale | 9.33 | 1,451 | 13,538 | 151,988 | Aug 19 05:00 PM | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Jun 17 '24 | Sale | 8.98 | 2,315 | 20,800 | 144,704 | Jun 18 05:56 PM | Parlavecchio Caryn | CHRO | Jun 17 '24 | Sale | 8.98 | 4,305 | 38,680 | 153,439 | Jun 18 05:55 PM | Myles Edward H | COO & CFO | Jun 17 '24 | Sale | 8.98 | 9,458 | 84,978 | 201,518 | Jun 18 05:54 PM | Ho Junlin | GENERAL COUNSEL | Jun 17 '24 | Sale | 8.98 | 4,695 | 42,183 | 204,076 | Jun 18 05:53 PM | Myles Edward H | COO & CFO | Feb 16 '24 | Sale | 15.74 | 4,744 | 74,686 | 210,976 | Feb 21 06:13 PM | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Feb 16 '24 | Sale | 15.74 | 2,512 | 39,547 | 147,019 | Feb 20 04:58 PM | Parlavecchio Caryn | CHRO | Feb 16 '24 | Sale | 15.74 | 3,751 | 59,053 | 157,744 | Feb 20 04:52 PM | Ho Junlin | GENERAL COUNSEL | Feb 16 '24 | Sale | 15.74 | 3,489 | 54,928 | 208,771 | Feb 20 04:48 PM | Backstrom Jay T. | CHIEF EXECUTIVE OFFICER | Feb 16 '24 | Sale | 15.74 | 11,614 | 182,842 | 352,671 | Feb 20 04:46 PM | Qatanani Mo | SVP AND HEAD OF RESEARCH | Jan 16 '24 | Sale | 15.93 | 2,002 | 31,889 | 78,816 | Jan 18 04:11 PM | Parlavecchio Caryn | CHRO | Jan 16 '24 | Sale | 15.93 | 2,849 | 45,381 | 114,350 | Jan 18 04:08 PM | Myles Edward H | COO & CFO | Jan 16 '24 | Sale | 15.93 | 6,634 | 105,670 | 162,150 | Jan 18 04:07 PM | Ho Junlin | GENERAL COUNSEL | Jan 16 '24 | Sale | 15.93 | 4,186 | 66,677 | 154,405 | Jan 18 04:05 PM | Myles Edward H | COO & CFO | Dec 29 '23 | Option Exercise | 4.86 | 12,459 | 60,551 | 181,243 | Dec 29 07:13 PM | Myles Edward H | COO & CFO | Dec 29 '23 | Sale | 18.83 | 12,459 | 234,633 | 168,784 | Dec 29 07:13 PM | Qatanani Mo | SVP AND HEAD OF RESEARCH | Dec 14 '23 | Option Exercise | 10.00 | 8,437 | 84,370 | 105,480 | Dec 15 04:13 PM | Qatanani Mo | SVP AND HEAD OF RESEARCH | Dec 14 '23 | Sale | 18.18 | 24,662 | 448,444 | 80,818 | Dec 15 04:13 PM | Myles Edward H | COO & CFO | Dec 07 '23 | Option Exercise | 4.86 | 24,914 | 121,082 | 193,698 | Dec 08 04:12 PM | Myles Edward H | COO & CFO | Dec 07 '23 | Sale | 17.53 | 24,914 | 436,820 | 168,784 | Dec 08 04:12 PM | Myles Edward H | COO & CFO | Nov 02 '23 | Sale | 12.51 | 35,007 | 438,039 | 168,784 | Nov 03 06:11 PM | AKKARAJU SRINIVAS | Director | Oct 16 '23 | Buy | 6.85 | 2,189,781 | 15,000,000 | 6,788,609 | Oct 18 05:46 PM | Samsara BioCapital GP, LLC | 10% Owner | Oct 16 '23 | Buy | 6.85 | 2,189,781 | 15,000,000 | 6,788,609 | Oct 18 05:44 PM | Invus Public Equities, L.P. | 10% Owner | Oct 12 '23 | Buy | 6.86 | 2,199,931 | 15,086,736 | 11,259,438 | Oct 16 05:46 PM | Qatanani Mo | SVP AND HEAD OF RESEARCH | Sep 18 '23 | Sale | 6.34 | 1,945 | 12,331 | 97,043 | Sep 20 07:28 PM |
|